Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

<p>&#8211; PDUFA target action date is May 25, 2024 &#8211; &#8211; FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA &#8211; CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) &#8212; Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/abeona-therapeutics-announces-fda-accepts-and-grants-priority-review-for-pz-cel-biologics-license-application-bla/">Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *